First-in-Humans Evaluation of Safety and Dosimetry of 64Cu-LLP2A for PET Imaging
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Nuclear Medicine"
DOI: 10.2967/jnumed.122.264349
Abstract: Visual Abstract There remains an unmet need for molecularly targeted imaging agents for multiple myeloma (MM). The integrin very late antigen 4 (VLA4), is differentially expressed in malignant MM cells and in pathogenic inflammatory microenvironmental… read more here.
Keywords: time; safety; 64cu llp2a; pet ... See more keywords